Why the study?
Angioimmunoblastic T-cell lymphoma is a highly aggressive subtype of peripheral T-cell lymphoma with unsatisfactory prognosis under current first-line standard of care, requiring more effective treatment options.
Does the CMOP regimen containing mitoxantrone hydrochloride liposome induce remission with acceptable safety in patients with angioimmunoblastic T-cell lymphoma?
Case Report (n=5)
No
Does the CMOP regimen containing mitoxantrone hydrochloride liposome induce remission with acceptable safety in patients with angioimmunoblastic T-cell lymphoma?
Answers are grounded in this paper and cite their sources.
The CMOP regimen containing mitoxantrone hydrochloride liposome shows promise as an effective and less cardiotoxic induction therapy for angioimmunoblastic T-cell lymphoma.
Angioimmunoblastic T-cell lymphoma (AITL) is a highly aggressive subtype of peripheral T-cell lymphoma. The current prognosis with the first-line standard of care remains unsatisfactory, necessitating the exploration of more effective treatment options. We reported 5 cases of AITL receiving CMOP (mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine, and prednisone). Cases 1 and 2 initially received CHOP as first-line induction therapy but switched to CMOP due to inadequate efficacy and cardiac adverse events. Cases 3, 4, and 5 were newly diagnosed and received CMOP. All patients achieved complete remission with acceptable cardiotoxicities and hematologic toxicities. After study treatment discontinuation, Cases 1 and 3 underwent autologous stem cell transplantation, and Cases 4 and 5 received oral maintenance agents. At the last follow-up, 4 patients remained in remission and 1 (Case 2) exhibited tumor recurrence. CMOP showed promise as a potential treatment option for AITL patients. Further research is essential to identify its efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Liang et al. (2024) conducted a case report in Angioimmunoblastic T-cell lymphoma (AITL) (n=5). CMOP regimen (mitoxantrone hydrochloride liposome, cyclophosphamide, vincristine/vindesine, and prednisone) was evaluated on Complete remission (CR).
Synapse has enriched 10 related papers. Consider them for comparative context: